德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06996 德琪医药-B

已收盘 06-01 16:09:06

1.810

-0.040

-2.16%

最高1.990	最低1.800	成交量148.05万
今开1.990	昨收1.850	日振幅10.27%
总市值12.22亿	流通市值12.22亿	总股本6.75亿
成交额274.37万	换手率0.22%	流通股本6.75亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06996","market":"HK","secType":"STK","nameCN":"德琪医药-B","latestPrice":1.81,"timestamp":1685606946041,"preClose":1.85,"halted":0,"volume":1480500,"delay":0,"floatShares":674888744,"shares":674888744,"eps":-1.0729071,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.04,"latestTime":"06-01 16:09:06","open":1.99,"high":1.99,"low":1.8,"amount":2743700,"amplitude":0.102703,"askPrice":1.84,"askSize":7500,"bidPrice":1.8,"bidSize":64500,"shortable":3,"etf":0,"ttmEps":-1.0729070711880337,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1685669400000},"adr":0,"listingDate":1605801600000,"adjPreClose":1.85,"volumeRatio":0.681992,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06996/wiki","defaultTab":"wiki","newsList":[{"id":"2340233282","title":"德琪医药(6996.HK)：希维奥二线治疗方案获纳入澳大利亚药品福利计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2340233282","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2340233282?lang=zh_CN&edition=full","pubTime":"2023-06-01 10:02","pubTimestamp":1685584942,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-06-01/doc-imyvtwai9328362.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-06-01/doc-imyvtwai9328362.shtml","is_publish_highlight":false},{"id":"2339673622","title":"德琪医药-B盘中异动 早盘急速下挫5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2339673622","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2339673622?lang=zh_CN&edition=full","pubTime":"2023-05-31 10:45","pubTimestamp":1685501103,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202305311045038472d9ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202305311045038472d9ca&s=b","is_publish_highlight":false},{"id":"2337092460","title":"重磅！美国FDA接连授予德琪医药（6996.HK）Claudin 18.2抗体偶联药物两项孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2337092460","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2337092460?lang=zh_CN&edition=full","pubTime":"2023-05-24 17:20","pubTimestamp":1684920030,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=8377bc9df6fef435e1f4efbe14cb4f03","is_publish_highlight":false},{"id":"2337934826","title":"德琪医药-B盘中异动 股价大跌5.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2337934826","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2337934826?lang=zh_CN&edition=full","pubTime":"2023-05-23 14:39","pubTimestamp":1684823976,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023052314393682cb3153&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023052314393682cb3153&s=b","is_publish_highlight":false},{"id":"2336324614","title":"FDA批准！德琪医药（6996.HK）ATG-031成为全球首个进入临床的抗CD24单抗","url":"https://stock-news.laohu8.com/highlight/detail?id=2336324614","media":"权证网","top":-1,"share":"https://www.laohu8.com/m/news/2336324614?lang=zh_CN&edition=full","pubTime":"2023-05-18 09:38","pubTimestamp":1684373921,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023051809384383c6d96f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023051809384383c6d96f&s=b","is_publish_highlight":false},{"id":"2336230933","title":"德琪医药-B：ATG-031的I期药效试验获美国FDA的IND许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2336230933","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2336230933?lang=zh_CN&edition=full","pubTime":"2023-05-18 07:52","pubTimestamp":1684367552,"startTime":"0","endTime":"0","summary":"德琪医药-B（06996）发布公告，首款潜力的抗CD24单克隆抗体药物ATG-031的I期研究的临床研究用新药（IND）申请已获美国食品药品监督管理局（FDA）许可。\n　　药效试验是用于治疗晚期实体瘤或B细胞非霍奇金淋巴瘤（B-NHL）患者的ATG031首次人体、多中心、开放性I期剂量研究。该研究的主要目的是评估ATG-031作为单一疗法的安全性和耐受性，并确定II期研究的适当剂量。次要目的是列明其在药理学的特色、评估免疫原性及评估ATG-031的初步疗效（如可行）。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/tob/2023-05-18/doc-imyueakh8534075.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/tob/2023-05-18/doc-imyueakh8534075.shtml","is_publish_highlight":false},{"id":"2336340305","title":"德琪医药-B(06996.HK)：用于治疗晚期实体瘤或B-NHL患者的ATG-031的I期药效试验获美国FDA的IND许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2336340305","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2336340305?lang=zh_CN&edition=full","pubTime":"2023-05-18 06:34","pubTimestamp":1684362875,"startTime":"0","endTime":"0","summary":"来源：格隆汇格隆汇5月18日丨德琪医药-B(06996.HK)发布公告，首款潜力的抗CD24单克隆抗体药物ATG-031的I期研究的临床研究用新药(“IND”)申请已获美国食品药品监督管理局(“FDA”)许可。药效试验是用于治疗晚期实体瘤或B细胞非霍奇金淋巴瘤(B-NHL)患者的ATG031首次人体、多中心、开放性I期剂量研究。该研究的主要目的是评估ATG-031 作为单一疗法的安全性和耐受性，并确定II期研究的适当剂量。次要目的是列明其在药理学的特色、评估免疫原性及评估ATG-031的初步疗效(如可行)。 \n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-05-18/doc-imyucwai2625926.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-05-18/doc-imyucwai2625926.shtml","is_publish_highlight":false},{"id":"2336347434","title":"德琪医药-B(06996)：ATG-031的I期药效试验获美国FDA的IND许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2336347434","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2336347434?lang=zh_CN&edition=full","pubTime":"2023-05-18 06:13","pubTimestamp":1684361600,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/932026.html","is_publish_highlight":false},{"id":"2336325627","title":"全球最权威创新药大会之一将召开，多家A股公司将亮相","url":"https://stock-news.laohu8.com/highlight/detail?id=2336325627","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2336325627?lang=zh_CN&edition=full","pubTime":"2023-05-17 16:04","pubTimestamp":1684310685,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023051716031384719b65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023051716031384719b65&s=b","is_publish_highlight":false},{"id":"2336361434","title":"喜讯！德琪医药希维奥在印度尼西亚的新药上市申请已成功递交","url":"https://stock-news.laohu8.com/highlight/detail?id=2336361434","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2336361434?lang=zh_CN&edition=full","pubTime":"2023-05-17 15:35","pubTimestamp":1684308919,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=06b89349281d06e92f1e26d0b0413b3b","is_publish_highlight":false},{"id":"2336936134","title":"喜讯！德琪医药（6996.HK）希维奥®（塞利尼索片）在印度尼西亚的新药上市申请已成功递交","url":"https://stock-news.laohu8.com/highlight/detail?id=2336936134","media":"权证网","top":-1,"share":"https://www.laohu8.com/m/news/2336936134?lang=zh_CN&edition=full","pubTime":"2023-05-17 14:57","pubTimestamp":1684306651,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023051714573283c4b69f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023051714573283c4b69f&s=b","is_publish_highlight":false},{"id":"2336046359","title":"德琪医药-B盘中异动 早盘大幅跳水6.54%报2.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2336046359","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2336046359?lang=zh_CN&edition=full","pubTime":"2023-05-17 10:48","pubTimestamp":1684291717,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023051710483780658a26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023051710483780658a26&s=b","is_publish_highlight":false},{"id":"2335525888","title":"德琪医药-B盘中异动 早盘股价大跌5.69%报2.321港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2335525888","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2335525888?lang=zh_CN&edition=full","pubTime":"2023-05-15 10:13","pubTimestamp":1684116805,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023051510132582c8e6e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023051510132582c8e6e1&s=b","is_publish_highlight":false},{"id":"2334506520","title":"德琪医药-B盘中异动 股价大跌5.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2334506520","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2334506520?lang=zh_CN&edition=full","pubTime":"2023-05-12 15:04","pubTimestamp":1683875052,"startTime":"0","endTime":"0","summary":"2023年05月12日下午盘15时04分，德琪医药-B股票出现异动，股价大幅下挫5.34%。截至发稿，该股报2.481港元/股，成交量151.25万股，换手率0.22%，振幅6.87%。德琪医药-B股票所在的药品行业中，整体涨幅为0.03%。德琪医药-B公司简介：德琪医药有限公司是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司。该公司主要在亚太地区开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023051215041282c8770c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023051215041282c8770c&s=b","is_publish_highlight":false},{"id":"2330598819","title":"德琪医药-B盘中异动 股价大涨5.59%报2.831港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2330598819","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2330598819?lang=zh_CN&edition=full","pubTime":"2023-04-28 09:38","pubTimestamp":1682645937,"startTime":"0","endTime":"0","summary":"2023年04月28日早盘09时38分，德琪医药-B股票出现波动，股价急速上涨5.59%。截至发稿，该股报2.831港元/股，成交量4000股，换手率0.00%，振幅3.36%。德琪医药-B股票所在的药品行业中，整体涨幅为0.11%。其相关个股中，康龙化成、顺腾国际控股、康臣药业涨幅较大，振幅较大的相关个股有山东新华制药股份、康哲药业、丽珠医药，振幅分别为4.86%、3.77%、3.38%。该公司主要在亚太地区开展业务。消息层面，截至09时38分，德琪医药-B股票正面舆情新闻比例69.23%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230428093857846fed38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230428093857846fed38&s=b","is_publish_highlight":false},{"id":"2330897733","title":"德琪医药-B盘中异动 早盘快速跳水5.05%报2.631港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2330897733","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2330897733?lang=zh_CN&edition=full","pubTime":"2023-04-25 09:57","pubTimestamp":1682387822,"startTime":"0","endTime":"0","summary":"2023年04月25日早盘09时57分，德琪医药-B股票出现异动，股价快速跳水5.05%。截至发稿，该股报2.631港元/股，成交量45.05万股，换手率0.07%，振幅3.97%。德琪医药-B股票所在的药品行业中，整体跌幅为0.54%。其相关个股中，兴科蓉医药、华控康泰、满贯集团涨幅较大，振幅较大的相关个股有山东新华制药股份、先声药业、华控康泰，振幅分别为9.76%、6.83%、6.82%。该公司主要在亚太地区开展业务。消息层面，截至09时57分，德琪医药-B股票正面舆情新闻比例28.57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230425095703846f6d3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230425095703846f6d3c&s=b","is_publish_highlight":false},{"id":"2330894559","title":"【券商聚焦】交银国际首予德琪医药－Ｂ(06996)买入评级 目标价4.79港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2330894559","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2330894559?lang=zh_CN&edition=full","pubTime":"2023-04-25 08:47","pubTimestamp":1682383668,"startTime":"0","endTime":"0","summary":"交银国际发研报称，该行首予德琪医药买入评级，目标价4.79港元。截至2022年12月31日，公司现金和银行结余为约17.9亿元，较可比公司充裕。公司计划在2024年推进多个具有全球权益的分子启动关键性临床研究，相关靶点目前均无产品上市，该行认为其价值并未充分反映在估值中。该行预计公司2023/24/25年销售收入3.51/6.33/9.95亿元，同比增长119.4%/80.1%/57.3%。采用DCF估值，假设WACC11.2%，永续增长率2%，得出公司合理估值为32.32亿港元，对应2023/24/25年市销率为7.9/4.4/2.8倍。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=3a2c3a9638e9053a9553cb02c76db9f3","is_publish_highlight":false},{"id":"2329886228","title":"浦银国际：维持德琪医药“买入”评级 目标价5.40港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2329886228","media":"媒体滚动","top":-1,"share":"https://www.laohu8.com/m/news/2329886228?lang=zh_CN&edition=full","pubTime":"2023-04-24 13:22","pubTimestamp":1682313763,"startTime":"0","endTime":"0","summary":"　　尽管面临疫情冲击，希维奥于2022年5月上市后依旧录得1.6亿元销售，我们预计随着商业化覆盖面扩大、新适应症获批，在授权地区的最终销售峰值有望达到20亿元左右。我们认为公司的长期价值依旧远被低估，维持“买入”评级并下调目标价至5.40港元。　　随着国内疫情缓解后患者就诊、用药恢复正常，我们预计希维奥将快速渗透目标市场，2023/24/25E 国内销售将大幅增长至3.4亿/5.8亿/8.3亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2023-04-24/doc-imyrnefk4780878.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2023-04-24/doc-imyrnefk4780878.shtml","is_publish_highlight":false},{"id":"2329094340","title":"国元国际：德琪医药（6996.HK）塞利尼索在AACR发布临床数据，市场空间广阔","url":"https://stock-news.laohu8.com/highlight/detail?id=2329094340","media":"权证网","top":-1,"share":"https://www.laohu8.com/m/news/2329094340?lang=zh_CN&edition=full","pubTime":"2023-04-24 10:35","pubTimestamp":1682303700,"startTime":"0","endTime":"0","summary":"使用60mg 塞利尼索第12周，疗效可评估患者：83.3%达到SVR35，80.0%达到TSS50；第24周疗效可评估患者：91.7%达到SVR35，77.8%达到TSS50。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230424103503827ebf57&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230424103503827ebf57&s=b","is_publish_highlight":false},{"id":"2329082030","title":"【券商聚焦】浦银国际下调德琪医药(06996)目标价至5.4港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2329082030","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2329082030?lang=zh_CN&edition=full","pubTime":"2023-04-24 09:24","pubTimestamp":1682299491,"startTime":"0","endTime":"0","summary":"浦银国际发研报指，尽管面临疫情冲击，德琪医药的核心产品希维奥于2022年5月上市后依旧录得1.6亿元销售，该行预计随着商业化覆盖面扩大、新适应症获批，在授权地区的最终销售峰值有望达到20亿元左右。该行预计希维奥将快速渗透目标市场，2023/24/25年国内销售将大幅增长至3.4亿/5.8亿/8.3亿元，且2023-25年海外销售也将快速爬坡，长期内海外将贡献整体产品销售的25-30%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=8bef06d5d028af22c6802d5b117a0bb8","is_publish_highlight":false}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.1148},{"period":"1month","weight":-0.3148},{"period":"3month","weight":-0.5363},{"period":"6month","weight":-0.5488},{"period":"1year","weight":-0.7409},{"period":"ytd","weight":-0.6408}],"websiteUrl":"http://www.antengene.com","compareEarnings":[{"period":"1week","weight":-0.0461},{"period":"1month","weight":-0.0835},{"period":"3month","weight":-0.1075},{"period":"6month","weight":-0.0236},{"period":"1year","weight":-0.1485},{"period":"ytd","weight":-0.0782}],"name":"德琪医药-B","description":"德琪医药有限公司是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司。该公司主要从事生物科技产品的发现、开发、生产及商业化。该公司的主要产品包括用于治疗复发╱难治性多发性骨髓瘤、复发╱难治性弥漫大B细胞淋巴瘤和非小细胞肺癌的ATG-010(selinexor)及用于治疗肝细胞癌和非小细胞肺癌等多种适应症的ATG-008(onatasertib)。该公司主要在亚太地区开展业务。","exchange":"SEHK","nameEN":"ANTENGENE-B","compareStock":{"symbol":"HSI","name":"恒生指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.13.0","shortVersion":"4.13.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供德琪医药-B(06996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"德琪医药-B,06996,德琪医药-B股票,德琪医药-B股票老虎,德琪医药-B股票老虎国际,德琪医药-B行情,德琪医药-B股票行情,德琪医药-B股价,德琪医药-B股市,德琪医药-B股票价格,德琪医药-B股票交易,德琪医药-B股票购买,德琪医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供德琪医药-B(06996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}